Erratum: Effect of high-vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: the OPTIMAL randomized clinical trial (JAMA (2022) 328:4 (336-347) DOI: 10.1001/jama.2022.10725);Effect of High-vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial

JAMA

Volumn 328, Issue 4, 2022, Pages 336-347

  Shi, Jia ^a   Zhou, Chenghui ^a   Pan, Wei ^b   Sun, Hansong ^a   Liu, Sheng ^a   Feng, Wei ^a   Wang, Weijian ^c   Cheng, Zhaoyun ^d   Wang, Yang ^a   Zheng, Zhe ^a,e  

^a FUWAI HOSPITAL   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d ZHENGZHOU UNIVERSITY   (China)

^e Central China Branch of National Center for Cardiovascular Diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; ADVERSE EVENT; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOPULMONARY BYPASS; CHINA; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART SURGERY; HUMAN; HUMAN CELL; INCIDENCE; ISCHEMIC STROKE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SEIZURE; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES;

ADULT; ANTIFIBRINOLYTIC AGENTS; CARDIAC SURGICAL PROCEDURES; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEIZURES; TRANEXAMIC ACID;

EID: 85135004173     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2022.19835     Document Type: Erratum

References (25)

1. Okamoto S, Okamoto U. Amino-methyl-cyclohexane-carboxylic acid: AMCHA: A new potent inhibitor of the fibrinolysis. Keio J Med. 1962; 11 (3): 105-115. doi: 10.2302/kjm.11.105
2. Couture P, Lebon JS, Laliberté É, Low-dose versus high-dose tranexamic acid reduces the risk of nonischemic seizures after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2017; 31 (5): 1611-1617. doi: 10.1053/j.jvca.2017.04.026 28803773
3. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010; 110 (2): 350-353. doi: 10.1213/ANE.0b013e3181c92b23 19996135
4. Shi J, Ji H, Ren F, Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: A multicenter randomized trial. JAMA Surg. 2013; 148 (6): 538-547. doi: 10.1001/jamasurg.2013.1560 23426385
5. Myles PS, Smith JA, Forbes A,; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017; 376 (2): 136-148. doi: 10.1056/NEJMoa1606424 27774838
6. Myles PS, Smith JA, Kasza J,; ATACAS Investigators and ANZCA Clinical Trials Network. Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. J Thorac Cardiovasc Surg. 2019; 157 (2): 644-652.e9. doi: 10.1016/j.jtcvs.2018.09.113 30459103
7. Sigaut S, Tremey B, Ouattara A, Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology. 2014; 120 (3): 590-600. doi: 10.1097/ALN.0b013e3182a443e8 23903022
8. Dowd NP, Karski JM, Cheng DC, Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology. 2002; 97 (2): 390-399. doi: 10.1097/00000542-200208000-00016 12151929
9. Grassin-Delyle S, Tremey B, Abe E, Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth. 2013; 111 (6): 916-924. doi: 10.1093/bja/aet255 23880099
10. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology. 1995; 82 (2): 383-392. doi: 10.1097/00000542-199502000-00009 7856897
11. Jiménez JJ, Iribarren JL, Brouard M, Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: A randomized double-blind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg. 2011; 6: 138. doi: 10.1186/1749-8090-6-138 21999189
12. Karski JM, Dowd NP, Joiner R, The effect of three different doses of tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32°C). J Cardiothorac Vasc Anesth. 1998; 12 (6): 642-646. doi: 10.1016/S1053-0770(98)90235-X 9854660
13. Lambert W, Brisebois FJ, Wharton TJ, Carrier RC, Boyle D, Rowe BH. The effectiveness of low dose tranexamic acid in primary cardiac surgery. Can J Anaesth. 1998; 45 (6): 571-574. doi: 10.1007/BF03012711 9669014
14. Waldow T, Szlapka M, Haferkorn M, Bürger L, Plötze K, Matschke K. Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc. 2013; 55 (4): 457-468. doi: 10.3233/CH-131782 24113504
15. Shi J, Zhou C, Liu S, Outcome impact of different tranexamic acid regimens in cardiac surgery with cardiopulmonary bypass (OPTIMAL): Rationale, design, and study protocol of a multicenter randomized controlled trial. Am Heart J. 2020; 222: 147-156. doi: 10.1016/j.ahj.2019.09.010 32062173
16. Du Y, Xu J, Wang G, Comparison of two tranexamic acid dose regimens in patients undergoing cardiac valve surgery. J Cardiothorac Vasc Anesth. 2014; 28 (5): 1233-1237. doi: 10.1053/j.jvca.2013.10.006 24447498
17. Fergusson DA, Hébert PC, Mazer CD,; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008; 358 (22): 2319-2331. doi: 10.1056/NEJMoa0802395 18480196
18. Nuttall GA, Gutierrez MC, Dewey JD, A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth. 2008; 22 (2): 230-235. doi: 10.1053/j.jvca.2007.12.016 18375325
19. Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci. 1968; 146 (2): 642-658. doi: 10.1111/j.1749-6632.1968.tb20322.x 5254275
20. Fiechtner BK, Nuttall GA, Johnson ME, Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg. 2001; 92 (5): 1131-1136. doi: 10.1097/00000539-200105000-00010 11323334
21. Fuwai Hospital and National Center for Cardiovascular Diseases. Cardiovascular surgery outcomes 2018. Accessed May 31, 2019. https://www.fuwai.com/News/Articles/Index/211409
22. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006; 354 (4): 353-365. doi: 10.1056/NEJMoa051379 16436767
23. Manji RA, Grocott HP, Leake J, Seizures following cardiac surgery: The impact of tranexamic acid and other risk factors. Can J Anaesth. 2012; 59 (1): 6-13. doi: 10.1007/s12630-011-9618-z 22065333
24. Thygesen K, Alpert JS, Jaffe AS, Third universal definition of myocardial infarction. Eur Heart J. 2012; 33 (20): 2551-2567. doi: 10.1093/eurheartj/ehs184 22922414
25. Pataraia E, Jung R, Aull-Watschinger S, Skhirtladze-Dworschak K, Dworschak M. Seizures after adult cardiac surgery and interventional cardiac procedures. J Cardiothorac Vasc Anesth. 2018; 32 (5): 2323-2329. doi: 10.1053/j.jvca.2017.12.036 29398383